Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.
Khalilieh SG, Yee KL, Sanchez RI, Fan L, Anderson MS, Sura M, Laethem T, Rasmussen S, van Bortel L, van Lancker G, Iwamoto M.
Khalilieh SG, et al.
Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02016-18. doi: 10.1128/AAC.02016-18. Print 2019 May.
Antimicrob Agents Chemother. 2019.
PMID: 30783000
Free PMC article.
Conversely, previously published trials showed that coadministered CYP3A inducers (rifampin and rifabutin) decreased doravirine exposure by 88% and 50%, respectively (K. L. Yee, S. G. Khalilieh, R. I. Sanchez, R. Liu, et al., Clin Drug Investig 37:659-667, 2017 [htt …
Conversely, previously published trials showed that coadministered CYP3A inducers (rifampin and rifabutin) decreased doravirine exposure by …